ArticleJournal of molecular histology2026
The anti-ulcerative potential of Berberine on the rat model of inflammatory bowel disease.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a global inflammatory bowel disease (IBD) and is a chronic mucosal inflammation of the large intestine. UC is accompanied by the increment in the production and release of pro-inflammatory mediators. Due to the immunomodulatory potentials of Berberine (BBN), the present study aimed at examining its anti-ulcerogenic activity against experimentally induced ulcerative colitis (UC), by intrarectal instillation of 1 ml of 3% acetic acid (AA). Thirty adults female Wistar rats were divided into three groups: (1) Negative control, (2) AA-induced UC rats (intrarectal), (3) Treated AA-induced UC + BBN (50 mg/kg/day; orally). Biochemical, molecular, histopathological, and immunohistochemical investigations were conducted. Intrarectal administration of AA provoked several macroscopic and microscopic alterations in the colons of UC-induced rats, increased the colonic lipid peroxidation, upregulated the expression of nuclear factor kappa B (NF-κB), caspase-3, and interferon gamma (IFN-γ), increased levels of colonic inflammatory tumor necrosis factor-alpha (TNF-α), Interleukin-1 beta (IL-1β), and prostaglandin E 2 (PGE-2), and downregulated the immunoexpression of nuclear factor erythroid 2-related factor 2 (Nrf-2). In contrast, treatment of UC-rats with BBN exhibited curative activities manifested by downregulating the expression of NF-κB and caspase-3, reducing the colonic contents of malondialdehyde (MDA), TNF-α, IL-1β, and PGE-2; and activating Nrf-2 immunoexpression. This study evidenced the anti-ulcerative and colo-therapeutic potentials of BBN that might be ascribed to its anti-lipid peroxidation, anti-apoptotic, and anti-inflammatory activities.
Indexed as
Identifiers
41934501What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.